Compare Procter & Gamble Health with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs AJANTA PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH AJANTA PHARMA PROCTER & GAMBLE HEALTH/
AJANTA PHARMA
 
P/E (TTM) x 52.1 22.5 231.9% View Chart
P/BV x 4.7 4.0 119.1% View Chart
Dividend Yield % 10.1 0.9 1,129.7%  

Financials

 PROCTER & GAMBLE HEALTH   AJANTA PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
AJANTA PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5491,422 249.6%   
Low Rs1,301898 145.0%   
Sales per share (Unadj.) Rs511.4233.5 219.0%  
Earnings per share (Unadj.) Rs61.344.0 139.4%  
Cash flow per share (Unadj.) Rs74.052.2 141.9%  
Dividends per share (Unadj.) Rs440.009.00 4,888.9%  
Dividend yield (eoy) %18.10.8 2,338.0%  
Book value per share (Unadj.) Rs927.8255.1 363.7%  
Shares outstanding (eoy) m16.6088.02 18.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.75.0 95.5%   
Avg P/E ratio x39.626.4 150.0%  
P/CF ratio (eoy) x32.822.2 147.4%  
Price / Book Value ratio x2.64.5 57.5%  
Dividend payout %717.920.5 3,506.9%   
Avg Mkt Cap Rs m40,257102,081 39.4%   
No. of employees `0001.16.8 16.7%   
Total wages/salary Rs m1,3134,307 30.5%   
Avg. sales/employee Rs Th7,486.73,022.6 247.7%   
Avg. wages/employee Rs Th1,157.6633.4 182.8%   
Avg. net profit/employee Rs Th897.2569.1 157.7%   
INCOME DATA
Net Sales Rs m8,49020,554 41.3%  
Other income Rs m244211 115.7%   
Total revenues Rs m8,73420,765 42.1%   
Gross profit Rs m1,4825,664 26.2%  
Depreciation Rs m211721 29.3%   
Interest Rs m012 0.0%   
Profit before tax Rs m1,5145,143 29.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5631,273 44.2%   
Profit after tax Rs m1,0173,870 26.3%  
Gross profit margin %17.527.6 63.3%  
Effective tax rate %37.124.8 150.1%   
Net profit margin %12.018.8 63.7%  
BALANCE SHEET DATA
Current assets Rs m15,34311,812 129.9%   
Current liabilities Rs m1,9603,776 51.9%   
Net working cap to sales %157.639.1 403.2%  
Current ratio x7.83.1 250.2%  
Inventory Days Days4977 63.0%  
Debtors Days Days2882 34.9%  
Net fixed assets Rs m1,20914,398 8.4%   
Share capital Rs m166175 94.6%   
"Free" reserves Rs m15,23522,277 68.4%   
Net worth Rs m15,40122,452 68.6%   
Long term debt Rs m07 0.0%   
Total assets Rs m17,59526,962 65.3%  
Interest coverage xNM444.3-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 63.3%   
Return on assets %5.814.4 40.2%  
Return on equity %6.617.2 38.3%  
Return on capital %10.323.0 44.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63610,682 15.3%   
Fx outflow Rs m4,3682,102 207.8%   
Net fx Rs m-2,7328,580 -31.8%   
CASH FLOW
From Operations Rs m-1,3043,748 -34.8%  
From Investments Rs m12,697-2,228 -569.9%  
From Financial Activity Rs m-301-1,475 20.4%  
Net Cashflow Rs m11,09345 24,541.8%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 1.6 1,174.2%  
FIIs % 1.0 7.6 13.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.0 171.2%  
Shareholders   28,591 20,968 136.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  AUROBINDO PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; HCL Technologies & SBI Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a mixed note with stocks in the consumer durables sector.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 23, 2019 01:53 PM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS